Compounds > mk-3118
Page last updated: 2024-11-13

mk-3118

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ibrexafungerp: a glucan synthase inhibitor with antifungal activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46871657
CHEMBL ID4297513
SCHEMBL ID3479266
MeSH IDM0569976

Synonyms (30)

Synonym
mk-3118
SCHEMBL3479266
ibrexafungerp
scy-078
ibrexafungerp [who-dd]
1207753-03-4
(1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-15-((2r)- 2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8- ((2r)-3-methylbutan-2-yl)-14-(5-(pyridin-4-yl)-1h-1,2,4- triazol-1-yl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-2h,4h-1,4a-propanophenanthro(
A92JFM5XNU ,
mk-3118 free base
ibrexafungerp [inn]
mk3118
4h-1,4a-propano-2h-phenanthro(1,2-c)pyran-7-carboxylic acid, 15-((2r)-2-amino-2,3,3-trimethylbutoxy)-8-((1r)-1,2-dimethylpropyl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-(5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl)-, (1s,4ar,6as,
ibrexafungerp [usan]
unii-a92jfm5xnu
who 10597
DB12471
AKOS032946516
mk 3118
EX-A7291
BODYFEUFKHPRCK-ZCZMVWJSSA-N
(1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-15-[[(2r)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1r)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4h-1,4a-propano-2h-phenanthro
D11544
ibrexafungerp (usan)
Q27273787
CHEMBL4297513
DTXSID901336871
scy 078
(1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-15-((2r)-2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8-((2r)-3-methylbutan-2-yl)-14-(5-(pyridin-4-yl)-1h-1,2,4-triazol-1-yl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-2h,4h-1,4a-propanophenanthro(1,2
scy078
ibrexafungerpum

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events were primarily gastrointestinal and were mild to moderate in severity."( Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
Angulo, D; Azie, NE; Borroto-Esoda, K; Delchev, DA; Ghannoum, MA; Harriott, IA; Nyirjesy, P; Sobel, JD; Sobel, R, 2022)		0.72

Pharmacokinetics

ExcerptReferenceRelevance
" To examine clinically relevant effects of the potential interaction with SCY-078, this phase 1, open-label, 2-period crossover study evaluated the pharmacokinetic parameters of rosiglitazone, a sensitive substrate of CYP2C8 metabolism, in the absence and presence of SCY-078 dosed to therapeutically relevant SCY-078 concentration exposure after repeat dosing."( Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S, 2018)		0.48
" Pharmacokinetic (PK) parameters were compared to assess both the impact of steady-state SCY-078 on tacrolimus and the impact of tacrolimus on the PK of steady-state SCY-078."( Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S, 2019)		0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" This was a sequential, single-center, open-label phase 1 study to assess the drug-drug interaction potential between SCY-078 and tacrolimus during concomitant administration in healthy subjects."( Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S, 2019)		0.51

Bioavailability

ExcerptReferenceRelevance
"To evaluate the activity of the orally bioavailable enfumafungin derivative MK-3118 and comparator antifungal agents tested against a collection of 113 clinical isolates of Candida spp."( Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).
Castanheira, M; Jones, RN; Messer, SA; Motyl, MR; Pfaller, MA, 2013)		1
" Derivatives of enfumafungin are novel orally bioavailable glucan synthase inhibitors."( Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.
Andes, DR; Lepak, AJ; Marchillo, K, 2015)		0.64
"We studied the antifungal activity of SCY-078 (an orally bioavailable 1,3-β -d- glucan synthesis inhibitor), micafungin and fluconazole against the planktonic and sessile forms of 178 Candida and non- Candida isolates causing fungaemia in patients recently admitted to a large European hospital."( The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
Bouza, E; Escribano, P; Gómez-Perosanz, M; Guinea, J; Marcos-Zambrano, LJ, 2017)		0.46
"SCY-078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species."( Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S, 2019)		0.51
"To evaluate the safety and efficacy of two dosing regimens of oral ibrexafungerp (formerly SCY-078), a novel orally bioavailable β-glucan synthase inhibitor, in subjects with invasive candidiasis versus the standard of care (SOC) and to identify the dose to achieve target exposure (15."( MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Angulo, D; Helou, S; Pappas, PG; Powderly, WG; Pullman, J; Spec, A; Thompson, GR; Tobin, EH; Vazquez, J; Wring, SA, 2019)		0.51

Dosage Studied

ExcerptRelevanceReference
" To examine clinically relevant effects of the potential interaction with SCY-078, this phase 1, open-label, 2-period crossover study evaluated the pharmacokinetic parameters of rosiglitazone, a sensitive substrate of CYP2C8 metabolism, in the absence and presence of SCY-078 dosed to therapeutically relevant SCY-078 concentration exposure after repeat dosing."( Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S, 2018)		0.48
"To evaluate the safety and efficacy of two dosing regimens of oral ibrexafungerp (formerly SCY-078), a novel orally bioavailable β-glucan synthase inhibitor, in subjects with invasive candidiasis versus the standard of care (SOC) and to identify the dose to achieve target exposure (15."( MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Angulo, D; Helou, S; Pappas, PG; Powderly, WG; Pullman, J; Spec, A; Thompson, GR; Tobin, EH; Vazquez, J; Wring, SA, 2019)		0.51
"In a multinational, open-label study, patients with documented invasive candidiasis were randomized to receive step-down therapy to one of three treatment arms: two dosing regimens of novel oral ibrexafungerp or the SOC treatment following initial echinocandin therapy."( MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Angulo, D; Helou, S; Pappas, PG; Powderly, WG; Pullman, J; Spec, A; Thompson, GR; Tobin, EH; Vazquez, J; Wring, SA, 2019)		0.51
" In December 2022, Ibrexafungerp received FDA approval for once monthly dosing to decrease the incidence of RVVC."( Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Merjanian, L; Phillips, NA; Rocktashel, M, 2023)		0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1692957Antifungal activity against Candida tropicalis MY1012 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692917Antifungal activity against Candida albicans MY1055 infected in DBA/2 mouse model of disseminated candidiasis assessed as reduction in fungal burden in kidney by measuring log change in colony forming units at 25 mg/kg, po bid for 7 days by TOKA2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692912Dose normalized AUC in po dosed mouse2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692952Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at ED50, ip administered bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692924Dose normalized AUC in po dosed rat2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692928Dose normalized AUC in po dosed dog2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692925Oral bioavailability in rat2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692948Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at 12.5 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692966Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mouse survival at 1.56 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days relative to control2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692960Antifungal activity against Candida glabrata MY1381 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692910Antifungal activity against Aspergillus fumigatus MF5668 assessed inhibition of fungal growth by measuring morphological changes measured after 24 hrs by microscopy2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692919Antifungal activity against Candida albicans MY1055 infected in DBA/2 mouse model of disseminated candidiasis assessed as reduction in fungal burden in kidney by measuring log change in colony forming units at 6.25 mg/kg, po bid for 7 days by TOKA2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692932Dose normalized AUC in po rhesus monkey2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692958Antifungal activity against Clavispora lusitaniae MY1396 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692920Clearance in mouse2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692923Half life in rat2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692963Antifungal activity against Clavispora lusitaniae MY1396 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692933Oral bioavailability in rhesus monkey2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692942Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mouse survival at 3.125 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days relative to control2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692926Clearance in dog2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692918Antifungal activity against Candida albicans MY1055 infected in DBA/2 mouse model of disseminated candidiasis assessed as reduction in fungal burden in kidney by measuring log change in colony forming units at 12.5 mg/kg, po bid for 7 days by TOKA2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692961Antifungal activity against Candida krusei ATCC 6258 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692965Antifungal activity against Aspergillus fumigatus MF5668 assessed inhibition of fungal growth by measuring morphological changes in presence of 50% human serum measured after 24 hrs by microscopy2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692913Oral bioavailability in mouse2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692964Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692955Antifungal activity against Candida glabrata MY1381 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692922Clearance in rat2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692911Antifungal activity against Candida albicans MY1055 assessed as fungal growth inhibition measured after 24 hrs in presence of 50% mouse serum by liquid microdilution method2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692938Antifungal activity against Candida albicans MY1055 infected in ip dosed DBA/2 mouse model of disseminated candidiasis assessed as reduction in fungal burden in kidney administered bid for 7 days by TOKA2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692956Antifungal activity against Candida krusei ATCC 6258 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692947Antifungal activity against Aspergillus fumigatus MF5668 infected in ip dosed DBA/2N mouse assessed as 90% mouse survival administered bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692927Half life in dog2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692931Half life in rhesus monkey2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692972Antifungal activity against Candida albicans MY1055 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692908Inhibition of beta-1,3-glucan synthase in Candida albicans MY1055 microsomal membrane assessed as inhibition of TCA-insoluble material formation using UDP-[3H]-glucose as substrate incubated for 2 hrs in presence of GTP by radioactivity-based assay2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692954Antifungal activity against Candida albicans MY1055 assessed as reduction in fungal growth in presence of 50% mouse serum2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692929Oral bioavailability in dog2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692962Antifungal activity against Candida tropicalis MY1012 assessed as reduction in fungal growth2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692939Antifungal activity against Candida albicans MY1055 infected in DBA/2 mouse model of disseminated candidiasis assessed as reduction in fungal burden in kidney by measuring log change in colony forming units at 12.5 mg/kg, ip bid for 7 days by TOKA2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692921Half life in mouse2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692949Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at 6.25 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692941Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mouse survival at 6.25 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days relative to control2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692953Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at ED90, ip administered bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692971Antifungal activity against Candida albicans MY1055 assessed as fungal growth inhibition in presence of 50% mouse serum2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692940Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mouse survival at 12.5 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days relative to control2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692959Antifungal activity against Candida parapsilosis ATCC 22019 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692930Clearance in rhesus monkey2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692909Antifungal activity against Candida albicans MY1055 assessed as fungal growth inhibition measured after 24 hrs by liquid microdilution method2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692967Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at 1.56 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
AID1692950Antifungal activity against Aspergillus fumigatus MF5668 infected in DBA/2N mouse assessed as mean survival time at 3.125 mg/kg, ip bid administered for 7 days starting from 15 to 30 mins post infection and measured up to 21 days2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's21 (44.68)24.3611
2020's26 (55.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.38 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (12.50%)5.53%
Reviews10 (20.83%)6.00%
Case Studies1 (2.08%)4.05%
Observational0 (0.00%)0.25%
Other31 (64.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
citric acid, anhydrous
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.		2.3110tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		7.8582conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		3.2710azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		4.18201,2,3-triazole
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		2.1510conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
rosiglitazone
[no description available]		3.5611aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		2.6320antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
albaconazole
albaconazole: UR-9825 is the (1R,2R)-isomer; structure in first source		3.2710
epiglucan
epiglucan: a highly side-chain/branched alkali-insoluble cell wall glucan from fungus such as Epicoccum nigrum, Botrytis cinerea, ascomycetes & basidiomycetes; also isolated S-4001 from Lei Wan (polyporus mylitiae), HA-beta-glucan from mushroom Pleutotus ostreatus (Fr.) Quel., and translam from seaweed Laminaria cichorioides; with commercially important functional properties including emulsification and friction reduction.		4.1740
laminaran
beta-1,3-glucan: component of fungal cell walls; also used as antitumor polysaccharide; unspecified D usually means BETA-GLUCANS; beta-1,3-D-glucan is also available; glucan phosphate is also available; biosynthesis is inhibited by echinocandins (cyclic hexapeptides). laminarin : A polysaccharide composed of beta-(1->3)-linked glucose residues containing sporadic beta-(1->6)-linkages as branch points or inter-residue linkages and 2-3% D-mannitol at some reducing termini.		2.9130
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		3.5911macrolide lactambacterial metabolite;
immunosuppressive agent
l 743,872
[no description available]		2.5220
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		3.9721antibiotic antifungal drug;
echinocandin		antiinfective agent
glycosides
[no description available]		12.87426
cancidas
[no description available]		2.3110
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.520antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
isavuconazole
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.		3.25101,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
enfumafungin
enfumafungin: from endophytic Hormonema species; structure in first source. enfumafungin : A triterpene glycoside and hemiacetal isolated from a fermentation of Hormonema sp. and which specifically inhibits glucan synthesis in fungal cells.		2.6620lactol;
monosaccharide derivative;
triterpenoid saponin		antifungal agent
t-2307
T-2307: antimalarial		3.2710
vt-1161
VT-1161: has antifungal activity		3.2710organic molecular entity
ConditionIndicatedRelationship StrengthStudiesTrials
Aspergillus Infection
[description not available]		02.3110
Candida Infection
[description not available]		05.71100
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		04.9940
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.		14.3110
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		05.71100
Candidiasis, Genital
[description not available]		09.67133
Candidiasis, Vulvovaginal
Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.		111.67133
Candidemia
A form of invasive candidiasis where species of CANDIDA are present in the blood.		14.7620
Acute Disease
Disease having a short and relatively severe course.		03.811
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.8120
2019 Novel Coronavirus Disease
[description not available]		02.610
Fungemia
The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.		02.610
Health Care Associated Infection
[description not available]		02.2510
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.2510
Aspergilloses, Bronchopulmonary
[description not available]		03.2310
Disseminated Fungal Infection
[description not available]		0420
Pulmonary Aspergillosis
Infections of the respiratory tract with fungi of the genus ASPERGILLUS.		03.2310
Candidiasis, Invasive
An important nosocomial fungal infection with species of the genus CANDIDA, most frequently CANDIDA ALBICANS. Invasive candidiasis occurs when candidiasis goes beyond a superficial infection and manifests as CANDIDEMIA, deep tissue infection, or disseminated disease with deep organ involvement.		17.5851
Fungal Diseases
[description not available]		03.9540
Mycoses
Diseases caused by FUNGI.		15.9540
Vulvovaginitis
Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS.		14.2110